HOME >> BIOLOGY >> NEWS
Society of Nuclear Medicine to offer first $25,000 Mallinckrodt Seed Grant

e considered until a satisfactory summary of an earlier grant is received.

This grant may supplement--not duplicate--other financial support. It will not pay institutional overhead costs or indirect costs, and no salary support will be provided for a principal investigator or co-principal investigators. The grant will be limited to a time span of one year, and no extensions will be allowed. Grantees are expected to submit results of the research as an abstract for presentation at SNM's Annual Meeting and/or as a scientific manuscript to the Journal of Nuclear Medicine.

SNM's grants and awards program is funded by both the Education and Research Foundation for the Society of Nuclear Medicine and the SNM Technologist Section (SNMTS) Professional Development and Education Fund. This program provides research grants and fellowships, educational scholarships and recognition awards to researchers, young investigators and students in nuclear medicine, molecular imaging and nuclear medicine technology. The Education and Research Foundation for SNM has been supporting the molecular imaging/nuclear medicine community since its founding in 1969. The foundation's mission is to advance excellence in health care through education and research in molecular imaging/nuclear medicine by provision of grants and awards.

"Providing molecular imaging/nuclear medicine professionals with increased support for cutting-edge research is one of the major priorities of SNM and the foundation," said ERF President Michael D. Devous Sr., Ph.D. "We are thankful that Tyco Healthcare/Mallinckrodt came forward to help us on this venture," he added.

For more information about this grant and application materials or to learn more about SNM, the foundation or making a contribution, please contact Kathy Bates, SNM's director of development, via phone at 703-708-9000, ext. 1028, or via e-mail at kbates@snm.org. Information is poste
'"/>

Contact: Maryann Verrillo
mverrillo@snm.org
703-708-9000
Society of Nuclear Medicine
13-Apr-2005


Page: 1 2 3

Related biology news :

1. American Chemical Societys Weekly PressPac -- Aug. 8, 2007
2. American Chemical Society meets Aug. 19-23 in Boston
3. American Chemical Societys Weekly PressPac -- Aug. 1, 2007
4. American Chemical Societys Weekly PressPac -- July 25, 2007
5. American Chemical Societys Weekly PressPac -- July 18, 2007
6. American Chemical Societys Weekly PressPac -- July 11, 2007
7. Tips from the Journals of the American Society for Microbiology
8. American Chemical Societys Weekly PressPac -- June 27/July 3, 2007
9. Health Physics Society
10. American Chemical Societys Weekly PressPac -- June 20, 2007
11. WPI professor to represent American Mathematical Society at exhibition on science funding

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Society Nuclear Medicine offer first Mallinckrodt Seed Grant

(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: